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The origin of thrombolytic therapy is briefly reviewed. It 
began 40 years ago with the demonstration that the injec- 
tion into patients of a partially purified activator of the 
native plasminogen-plasmin enzyme system was capable 
of dissolving clotted blood and fibrinous loculations in 
the chest. However, the application of this form of ther- 
apy for the dissolution of intravascular thrombi had to 
await a series of further developments, including exten- 
sive purification of the thrombolytic agents, evidence 
that plasminogen activators would be more appropriate 
than plasmin for thrombolysis and proof, first in ani- 
mals and then in humans, that thrombi could be dis- 
Thrombolytic therapy began in 1946, when William S. Tillett 
and I began an investigation of the clinical potential of 
partially purified streptokinase preparations for dissolving 
clotted blood and fibrinous exudates in patients. We chose 
hemothorax and empyema cases to initiate our studies 
because serial radiographs would allow us to observe the 
effects and samples of fluid could be removed for analysis. In 
1949, we published the first in vivo demonstration of the lysis 
of clotted human blood (1). 
In Figure 1, the results, in early 1947, of the jirst 
therapeutic test 0-f streptokinase in a patient are shown. The 
chest X-ray film is from a young man who had a loculated 
hemothorax after removal of the left lung and developed a 
high fever. We suspected an infection, but the small amounts 
of fluid that could be aspirated were sterile. By injecting 
400,000 LJ of streptokinase into the chest, we attempted to 
determine whether it was possible to dissolve the hemotho- 
rax and expose the infection. The results were dramatic. Six 
hours after the injection, fluoroscopy revealed the break- 
down of all the loculations and free mobility of the fluid in 
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solved by the systemic administration of plasminogen 
activators. 
The first study of thrombolytic therapy in acute myo- 
cardial infarction was reported in 1958. However, despite 
many studies conducted during the next 20 years, with 
encouraging reductions in mortality, thrombolytic therapy 
for acute myocardial infarction became established only 
when angiography provided visual evidence of the presence 
of a thrombus obstructing an infarct-related artery and of 
the achievement of prompt lysis with the administration of 
thrombolytic agents. 
(J Am Co11 Cardiol1989;14:1085-92) 
the chest. The chest X-ray film (Fig. 1) taken soon after the 
removal of 1,300 ml of lysed coagulum shows the pleural 
space drained of its previous contents. Fortunately, the fluid 
was sterile and the temperature spontaneously reverted to 
normal. 
History of thrombolytic therapy. The history of throm- 
bolytic therapy actually began in 1933 with the report by 
Tillett and Garner (2), which stated that Lancefield Group A 
beta-hemolytic streptococci isolated from patients produced 
a fibrinolytic substance. Tillett named this material strepto- 
coccal fibrinolysin. Although he envisioned that this sub- 
stance ultimately could be used to dissolve fibrinous exu- 
dates, he did not have the training to attempt to isolate or 
purify this substance. His expertise was in bacteriology and 
infectious diseases. His laboratory, however, attracted good 
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that a plasma factor, which he named “plasma lysing 
factor,” was necessary for streptococcal-mediated fibrino- 
lysis. In 1945, L. Royal Christensen (4), a microbiologist 
with good biochemical skills, worked out the mechanism of 
streptococcal tibrinolysis. He and MacLeod (5) pointed out 
that human plasma contained the precursor of an enzyme 
system, which he termed plasminogen, and that the strepto- 
coccal fibrinolysin, which he renamed streptokinase, was an 
activator or kinase that was capable of converting plasmino- 
gen to the proteolytic and fibrinolytic enzyme plasmin. They 
also pointed out that plasmin could digest fibrinogen as well 
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Figure 1. First demonstration in human 
patients of the efficacy of streptokinase 
in dissolving fibrin in loculated hemotho- 
rax for therapeutic purposes. See text for 
details. From Tillett and Sherry (1). 
as fibrin, and that the action of plasmin was buffered by the 
presence of inhibitors in plasma. 
In early 1947, Christensen (6) made available to Tillett 
partially purified preparations of streptokinase to be evalu- 
ated for their therapeutic potential in humans, and Tillett 
asked me to initiate the clinical investigation of this sub- 
stance. Figure 2 is a photograph taken on a ward of New 
York City’s Bellevue Hospital in 1949; Tillett, Christensen 
and I had been joined by Alan Johnson, a meticulous and 
dedicated investigator, and a research fellow, George Hazle- 
hurst, who subsequently left us to enter private practice. 
Johnson was given the task of initiating studies on intravas- 
cular thrombolysis in experimental animals, while Hazle- 
hurst worked with me on the clinical studies. 
Studies on streptokinase. Initially, the streptokinase 
preparation, which was only 10% pure and contained a 
deoxyribonuclease, hyaluronidase and other streptococcal 
enzymes, was used to treat hemothorax (7), acute postpneu- 
manic (8) and chronic empyemas (9) and to produce an 
enzymatic debridement of infected tissue spaces (10). Figure 
3 is a photograph of a group of patients we treated success- 
fully for a wide variety of conditions. 
The major interest in the development of the clot-lysing 
ability of streptokinase, however, was based on its ultimate 
Figure 2. Team involved in the pioneer- 
ing investigation of fibrinolytic ther- 
apy. Seated from left to right: George 
Hazlehurst, William S. Tillett and L. 
Royal Christensen. Standing from left 
to right: Alan Johnson and Sol Sherry. 
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Figure 3. Group of patients treated successfully for a 
wide variety of conditions with the enzyme prepara- 
tion provided by Christensen. Hazlehurst (left) and 
Sherry (right) are shown examining the remnants of a 
chronic neck infection in one of the patients. 
use in the treatment of acute coronary thrombosis. At the 
time, coronary thrombosis was a term used synonymously 
with acute myocardial infarction, a common medical prob- 
lem with a ~30% in-hospital mortality rate. The reason for 
this interest was that several well-known pathologists in the 
1930s (11,12) and again in the 1960s and 1970s (13,14) had 
pointed out that the most common cause of a myocardial 
infarction was a thrombus superimposed on the cracked 
surface of an atheromatous plaque. However, our streptoki- 
nase preparations elicited severe febrile reactions when 
administered intravenously or injected into closed spaces. 
Though these preparations were not suitable for intravenous 
therapy, Lederle Laboratories initiated a program to develop 
preparations that would be acceptable for intravenous ther- 
apy, and in 19.52, Johnson and Tillett (15) reported that 
experimental thrombi in rabbit ear veins could be lysed by 
the intravenous administration of streptokinase into a pe- 
ripheral vessel. 
Studies on plasminogen activator for thromholysis. 
Shortly thereafter, Daniel Kline, then at Yale University, 
developed a technique that allowed for purification of human 
plasminogen (16). Because human plasmin could now be 
prepared in vitro by the addition of streptokinase. it was 
possible to consider human plasmin, rather than streptoki- 
nase, for thrombolysis. However, in vitro studies on clot 
lysis (17) indicated that the rate of fibrinolysis and its 
selectivity as a process were dependent on the presence of 
both a plasminogen activator and plasminogen, but not on 
plasmin alone. 
The late 1950s proved to be a most productive period in 
the development of thrombolytic therapy. I was fortunate to 
he ;rrind in Ct T m,ic h,r +,rrn n,,tct>nrl;nn in,r~rt;natnr~ “1 J”nn.w” 111 “I. Y”UL.7 “J b..” “l.ALLI~ULI~.I.~ II,, W.JLlbULVL.7, 
Tony Fletcher and Norma Alkjaersig, later to become Mrs. 
Fletcher (Fig. 4). First we attacked the problem of whether 
it would be best to use a plasminogen activator or the 
fibrinolytic enzyme plasmin. A variety of observations, both 
in vitro and in vivo (17-20), led us to conclude that plasmin- 
ogen activators would be more successful as thrombolytic 
agents than would the proteolytic enzyme plasmin. This 
view was based mostly on the demonstration that the pri- 
mary and most sensitive mechanism for thrombolysis was 
the penetration of an activator into a thrombus, with activa- 
tion of the plasminogen that bound to fibrin during clotting 
(20). However, we knew that the intravenous infusion of a 
plasminogen activator like streptokinase would result in two 
different actions (Fig. 5). Diffusion of streptokinase into a 
thrombus would result in clot lysis, but the agent would also 
activate plasminogen in the systemic circulation, producing 
fibrinogenolysis and an impaired hemostatic mechanism. 
Studies on streptokinase for thrombolysis. In the mean- 
time, Lederle Laboratories had been successful in develop- 
ing purified preparations of streptokinase that were well 
tolerated by patients and, in the absence of trauma or 
invasive procedures, with few bleeding complications. In 
1957, we reported (21) on a rational approach to thrombol- 
ysis with streptokinase. It involved a loading dose and a 
sustaining infusion sufficient to increase the clot-dissolving 
activity of plasma several hundredfold and maintain a strep- 
tokinase concentration in plasma of about 10 drnl (Fig. 6, 
top panel). This resulted in a short-lived proteolytic state 
because, once the plasma plasminogen was exhausted, fi- 
brinogen levels began to rise even though the streptokinase 
infusion was being maintained (Fig. 6, second panel). How- 
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tained as long as streptokinase was being infused (Fig. 6, 
third panel). The therapy resulted in a prolongation of the 
prothrombin time (resulting from fibrinogenolysis) and the 
appearance of breakdown products (Fig. 6, bottom panel). 
Johnson, who had remained in New York, demonstrated 
that a similar system was effective in dissolving experimental 
thrombi in human volunteers. An intravenous infusion into 
the opposite arm resulted, in most cases, in lysis of the clot 
and reestablishment of the patency of the vessel (Fig. 7). 
First studies on acute myocardial infarction. The interest 
of our group, however, was to evaluate this regimen for 
clinical purposes, and in 1958, we reported (23) the first 
study of intravenously administered streptokinase in pa- 
tients with acute myocardial infarction. The stated objective 
then, as now, was that “the rapid resolution of a coronary 
thrombus by enzymatic means could result in reduction of 
the final area of muscle infarction, reduction of the degree of 
electrical instability present during the early critical phase of 
infarction, and prevent the appearance of or lyse mural 
thrombi (23).” Ours was primarily a pilot study to determine 
Figure 5. Dual effect of intravenously administered streptokinase. 
See text for details. 
w. 
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Figure 4. Team of investigators in St. Louis responsi- 
ble for establishing the basis of plasminogen activators 
for thrombolytic therapy and for a variety of throm- 
boembolic disorders including acute myocardial in- 
farction. Shown from left to right are the late Anthony 
P. Fletcher, Norma Alkjaersig and Sol Sherry. 
how well the patient and the heart would tolerate a 30 h 
infusion of streptokinase. 
Not only were we encouraged by the lack of complica- 
tions we observed, but patients treated within the first 14 h 
after symptom onset had a very low in-hospital mortality 
Figure 6. Serial biochemical determinations in a patient during a 
30 h infusion of streptokinase (SK) administered intravenously. See 
text for details. From Fletcher et al. (24). 
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Figure 7. Radiographic demonstration of the lysis 
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volunteer. Panel a. control venogram before the 
induction of the clot showing a patent vessel. Panel 
b, venogram taken 24 h after the induction of a clot 
by traumatizing the intima of an antecubital vein by 
a dental burr inserted through a needle. The ra- 
dioopaque lines at I and 2 were made by nichrome 
wires on the skin surface to define the extent of the 
clot; the arrow at 3 indicates the distal portion of 
the clot. Panel c, venogram 24 h after the streptoki- 
nase infusion, showing complete lysis of the clot 
without reformation. From Johnson and McCarty 
(22). 
rate (Table 1), whereas patients treated anywhere from 20 to 
72 h after symptom onset had a mortality rate similar to that 
of untreated patients. We also described (Fig. 8) the early 
peaking of serum transaminase in the streptokinase-treated 
patients (that is, at an average of 14 h rather than the 24 h as 
observed in untreated patients). 
The details of these studies, which provided the basis for 
the use of plasminogen activators as thrombolytic agents as 
well as our pharmacologic and clinical observations on 
intravenous therapy with streptokinase, were published in 
I959 (20 7,i ?C, ,..A “++,,,+,A ..,:,A, ,+t,..+;,.. I?L\ , L-t, LJ, dl,l_J alLlaLLC” W,UG allF,ILl”ll [L”,. As a 
result, a number of fellows who went on to become leaders 
in thrombosis research joined our research group. These 
included Nils Bang, Fedor Bachmann, who in 1964 while in 
our laboratory was responsible for the first major purification 
of a tissue plasminogen activator from pig heart (27), Robert 
Colman, Jack Hirsh, Heinz Joist, Zbigniew Latallo, George 
McNicol, Michael Mosesson, Josef Vermylen and Per 
Wallen. These fellows added much knowledge to the subject 
of fibrinolysis and helped in the clinical introduction of 
urokinase, a naturally occurring human activator whose 
preparation for clinical use was developed in conjunction 
with our group by Abbott Laboratories and Sterling- 
Winthrop (28). 
Table 1. Mortality in Patients With Acute Myocardial Infarction 
Treated With Streptokinase 
Early treatment 
(6 to 14 h) 
Delayed treatment 
(20 to 72 h) 
No. No. 
Treated Died 
15 1 
9 3 
Results of a 30 h infusion of intravenously administered streptokinase 
when treatment was begun 6 to 14 h after the onset of symptoms of acute 
myocardial infarction or when therapy started 20 to 72 h later. From Fletcher 
et al. (23). 
Lysis of pulmonary thrombi (urokinase and streptokinase). 
Pulmonary angiography was now an available technique, 
and this allowed for the demonstration of in vivo clot lysis of 
pulmonary emboli by urokinase and streptokinase as com- 
pared with heparin in National Institutes of Health- 
sponsored trials (29-31). Figure 9 shows the marked hypo- 
perfusion on the right lung resulting from a large embolus in 
the right main pulmonary artery (left panel) and its disap- 
pearance within 24 h, with the restoration of lung perfusion 
after a course of thrombolytic therapy (right panel). These 
triais taught us that iocai factors were more important in 
determining the success of therapy than were measurable 
activities in the systemic circulation, and that bleeding 
complications were related to the lysis of hemostatic plugs at 
sites of vessel injury and were unrelated to the extent of the 
hemostatic defect induced in the patient. 
Although a fixed dose regimen was introduced initially for 
urokinase. a great problem with the regimen we developed 
for streptokinase was that it required a considerable amount 
of laboratory control to determine the amount of the loading 
dose and then to adjust the sustaining infusion to maintain 
the desired level of activator activity in plasma. This prob- 
lem was overcome by Verstraete et al. (32), who developed 
a standard dose therapy based on a loading dose that proved 
to be effective in overcoming the antistreptokinase resis- 
tance of 290% in treated patients, and a fixed maintenance 
dose that sustained a fairly intense clot-dissolving state. 
When Lederle Laboratories ran into difficulties in quality 
control of streptokinase preparations, the 1960s and there- 
after saw the production of streptokinase undertaken by 
Behringwerke in Germany and Kabi in Sweden. Table 2, 
which is based on a review by Yusuf et al. (33), lists 18 trials 
of streptokinase and 4 of urokinase administered intrave- 
nously for the treatment of acute myocardial infarction. 
These trials were conducted between 1963 to 1979, usually 
by a 24 h infusion and most often within 12 to 24 h after 
wmntom nnwt Though come of these trials ypre ye!! I,___r_-___ _..___. 
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designed and conducted, for example, that of the European 
Cooperative Study Group (34,35), they were never taken 
seriously for the following reasons: 1) cardiologists no longer 
stressed coronary thrombosis as the cause of an acute infarct 
despite the view held by many leading pathologists on this 
subject during this period (36); 2) there were delays in 
Figure 9. Lysis of a large pulmonary embolus in the right main 
pulmonary artery by 1.2 h infusion of urokinase in the Urokinase- 
Pulmonary Embolism Trial (29-31). Left panel, pulmonary angio- 
gram before treatment; right panel, pulmonary angiogram 24 h later 
(that is, after treatment). See text for details. 
Figure 8. Serial serum glutamic oxaloacetic transami- 
nase (SGOT) observations in patients after the onset of 
an acute myocardial infarction who were treated with a 
30 h intravenous infusion of streptokinase. Note the 
early peaking of the serum transaminase at 14 h. From 
Fletcher et al. (23). 
admitting patients into trials because biometricians insisted 
that randomization be delayed until there were serial elec- 
trocardiographic changes and enzyme elevations; 3) coro- 
nary care units were coming into prominence, and most of 
the reported studies did not involve such units; 4) bleeding 
Table 2. Randomized Trials of Thrombolytic Therapy in Acute 
Myocardial Infarction Conducted Between 1959 and 1979 and 
Utilizing Sustained Intravenous Infusions of Streptokinase 
or Urokinase 
Streptokinase Urokinase 
Fletcher et al. (1959) 
Dewar et al. (1963) 
Amery et al. (1967) 
Heikenheimo et al. (1967) 
Dioguardi et al. (1971) 
European Working Party (1971) 
Bett et al. (1973) 
Breddin et al. (1973) 
Ness et al. (1974) 
Frank (1975) 
Valere et al. (1975) 
Klein et al. (1976) 
Aber et al. (1976) 
Australian (1977) 
Benda et al. (1977) 
Lasiera et al. (1977) 
Poliwoda et al. (1977) 
Wischitz et al. (1977) 
European Cooperative Study 
Group (1979) 
Lippschutz et al. (1965) 
Gormsen (1973) 
Brochier et al. (1975) 
European Collaborative Group (1975) 
Adapted from review by Yusuf et al. (33), which also cites references. 
Year of the report is shown in parentheses. 
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complications became more frequent as the number of 
invasive procedures increased; and 5) there was no tech- 
nique available for adequately measuring infarct size or 
ventricular function, Nevertheless, a retrospective meta 
analysis of these trials (33,37) indicated that overall there 
was a significant (approximately 20%) reduction in the 
mortality rate when the therapy, even though delayed, was 
carried out within the 1st day of infarction. 
Besides these trials with intravenous therapy, efforts at 
directly infusing a fibrinolytic agent into the coronary arter- 
ies of patients suffering from an acute myocardial infarction 
began with the ingenious approach of Boucek and Murphy 
(38) in 1960. Subsequently, Chazov et al. (39) described its 
accomplishment by coronary catheterization in 1976. 
Modern era thrombolytic therapy. This brings us to the 
modern era of thrombolytic therapy for acute myocardial 
infarction highlighted by: 1) its start by the demonstration by 
DeWood et al. (40) of a very high incidence of a total 
occlusion of the infarct-related artery when coronary angio- 
grams were performed within the first 4 h after symptom 
onset, and the evidence that these occlusions were throm- 
botic; 2) the demonstration by Rentrop et al. (41) that local 
instillation of streptokinase into the thrombotically occluded 
vessel early after symptom onset brought about rapid reca- 
nalization in most cases; and 3) the subsequent introduction 
of a high dose, brief duration intravenous thrombolytic 
regimen by Schroder et al. (42) designed to accelerate the 
rate of thrombolysis and decrease the incidence of bleeding 
complications. In addition, there has been the development 
of a number of new plasminogen activators including 
prourokinase (43). recombinant tissue-type plasminogen ac- 
tivator (rt-PA) (44) and anisoylated plasminogen streptoki- 
nase activator complex (APSAC) (45). 
Today, after a long developmental period, we are finally 
into the modern era of thrombolytic therapy for the initial 
treatment of an acute myocardial infarction. Ample evidence 
exists that the administration of a thrombolytic agent intra- 
venously early after symptom onset will limit myocardial 
damage and reduce mortality. 
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